Amendment: Director Graham G. Walmsley sold $4,730,137 worth of shares (700,761 units at $6.75) and bought $4,730,137 worth of shares (700,761 units at $6.75) (SEC Form 4)
$OLMA
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | |||||||||||||||||
| Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | |||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
Olema Pharmaceuticals, Inc. [ OLMA ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
|
3. Date of Earliest Transaction
(Month/Day/Year) 12/13/2024 | ||||||||||||||||||||||||||
|
4. If Amendment, Date of Original Filed
(Month/Day/Year) 12/17/2024 |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
| Code | V | Amount | (A) or (D) | Price | ||||||
| Common Stock(4) | 12/13/2024 | S(3) | 700,761 | D | $6.75 | 0 | I | See note(1) | ||
| Common Stock(5) | 12/13/2024 | P(3) | 700,761 | A | $6.75 | 700,761 | I | See note(2) | ||
| Common Stock | 708,114 | I | See note(6) | |||||||
|
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Explanation of Responses: |
| 1. The shares are held by Logos Opportunities Fund I LP ("Logos Fund I"). Logos Opportunities GP, LLC ("Logos Opportunities GP") is the general partner of Logos Fund I and the reporting person is a managing member of Logos Opportunities GP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. |
| 2. The shares are held by Logos Opportunities Fund IV LP ("Logos Fund IV"). Logos Opportunities IV GP LLC ("GP IV") is the general partner of Logos Fund IV and the reporting person is a managing member of GP IV. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. |
| 3. These securities were sold by Logos Fund I to Logos Fund IV. Logos Fund I and Logos Fund IV are under the common control of the Reporting Person. |
| 4. The Form 4 filed on December 17, 2024 identified the transaction date as December 17, 2024. The transaction date was December 13, 2024. |
| 5. The Form 4 filed on December 17, 2024, inadvertently reported the number of shares held by Logos Fund IV after the transaction as 1,408,875. As reported in this amended Form 4, the number of shares held by Logos Fund IV after the transaction is 700,761. The Form 4 also mistakenly reported the purchase of shares by Logos Fund IV as a disposition. The transaction was an acquisition. The transaction date was December 13, 2024. |
| 6. The shares are held by Logos Opportunities Fund II LP ("Logos Fund II"). Logos Opportunities GP is the general partner of Logos Fund II and the reporting person is a managing member of Logos Opportunities GP. The Form 4 filed on December 17, 2024, incorrectly reported these shares as being held by Logos Fund IV. |
| /s/ Graham Walmsley | 12/18/2024 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||